A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

Health Technology Assessment

Volumn 11, Issue 2, 2007, Pages

  Collins, R ^a   Fenwick, E ^a   Trowman, R ^a   Perard, R ^a   Norman, G ^a   Light, K ^a   Birtle, A ^b   Palmer, S ^a   Riemsma, R ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CLODRONIC ACID; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; FLUTAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYDROCORTISONE; MITOXANTRONE; OKANTRONE; OXYGEN; PACLITAXEL; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ERYTHROPOIETIN; STRONTIUM 89; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ZOLEDRONIC ACID; GLUCOCORTICOID; TAXOID;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BLADDER DISEASE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; COUGHING; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECONOMIC EVALUATION; EMBASE; ENDOCRINE DISEASE; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL DISEASE; GRANULOCYTE; GRANULOCYTOPENIA; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFORMATION RETRIEVAL; INSOMNIA; KIDNEY DISEASE; LACRIMATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DISEASE; LUNG DISEASE; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MEDLINE; MELANOMA; META ANALYSIS; METABOLIC DISORDER; METASTASIS; MONOTHERAPY; MONTE CARLO METHOD; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NAIL; NAIL DISEASE; NATIONAL HEALTH SERVICE; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OXYGEN THERAPY; PAIN; PERIPHERAL EDEMA; PROSTATE CANCER; PROSTATE SURGERY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SENSITIVITY ANALYSIS; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SKIN DISEASE; SKIN EXFOLIATION; SKIN TOXICITY; STOMACH IRRITATION; STOMATITIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TASTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; UNCERTAINTY; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; DRUG COMBINATION; ECONOMICS; MALE; PROSTATE TUMOR; STATISTICAL MODEL; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; MALE; MODELS, ECONOMIC; NEOPLASM METASTASIS; PREDNISONE; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; TAXOIDS; TREATMENT OUTCOME;

EID: 85045482908     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11020     Document Type: Review

References (283)

1. Cancer Research UK. CancerStats incidence - UK [web page on the Internet]. London: Cancer Research UK; 2004.URL: http://info.cancerresearchuk.org/cancerstats/incidence/. Accessed July 2005.
2. Cancer Research UK. CancerStats mortality - UK [web page on the Internet]. London: Cancer Research UK; 2004. URL: http://info.cancerresearchuk.org/cancerstats/mortality/. Accessed July 2005.
3. Office for National Statistics. Cancer survival: cancer survival trends by NHS region, selected cancers, patients diagnosed 1971-90: age-standardised relative survival rates (with 95% confidence intervals) at one and five years after diagnosis, and average increases in relative survival [web page on the Internet]. London: Office for National Statistics; 2002. URL: http://www.statistics.gov.uk/StatBase/ xsdataset.asp?More=Y&vlnk=977&All=Y&B2.x=72&B2.y=13. Accessed 18 January 2005.
4. Department of Health. Hospital episode statistics 2003-2004 [Pdf on the Internet]. London: Department of Health; 2004. URL: http://www.dh.gov.uk/ assetRoot/04/09/70/20/04097020.pdf. Accessed 18 January 2005.
5. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
6. Shaneyfelt T. Husein R, Bubley G, Mantzoros. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847-53.
7. Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, Abdulkarim B. Environmental, genetic, and molecular features of prostate cancer. Lancet oncol 2004;5:303-13.
8. National Institute for Clinical Excellence. Guidance on cancer services: improving outcomes in urological cancers: the manual. London: NICE; 2002.
9. Muthuramalingam SR, Patel K, Protheroe A. Management of patients with hormone refractory prostate cancer. Clin Oncol (R Coll Radiol) 2004;16:505-16.
10. Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N, et al. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 2004;90:1367-73.
11. Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997;1(3).
12. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
13. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002;20 (3 Suppl 1):31-5.
14. Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 1999;54 Suppl 6A:22-9.
15. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999;26(5 Suppl 17):3-7.
16. Aventis Pharma. Taxotere [summary of product characteristics]. Electronic Medicines Compendium; 2004. URL: http://emc.medicines.org.uk/ emc/assets/c/html/displaydoc.asp?documentid=4594. Accessed 6 January 2005.
17. The Royal College of Radiologists' Clinical Oncology Information Network, British Association of Urological Surgeons. Guidelines on the management of prostate cancer. Clin Oncol (R Coll Radiol) 1999;11:S53-88.
18. Joint Formulary Committee. British National Formulary. 49th ed. [book on the Internet]. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2005. URL: http://www.bnf.org/ bnf/. Accessed 15 August 2005.
19. National Horizon Scanning Centre. Docetaxel for hormone-reftactory prostate cancer [pdf on the Internet]. Birmingham: National Horizon Scanning Centre; 9-003. URL: http://www.pcpoh.bham.ac.uk/publichealth/ horizon/PDF_files/2003reports/docetaxel.pdf. Accessed 20 April 2005.
20. Center for Drug Evaluation and Research. Approval package for Novantrone. Application number 019297/S014 [pdf on the Internet]. Center for Drug Evaluation and Research; 1996. URL: http://www.fda.gov/cder/foi/ nda/96/019297_s014ap.pdf. Accessed 26 May 2005.
21. PDR drug information for Novantrone for injection concentrate [web page on the Internet]. URL: http://www.drugs.com/pdr/ mitoxantrone_hydrochloride.html. Accessed 24 August 2005.
22. Pharmacia Limited. Estracyt capsules [summary of product characteristics]. Electronic Medicines Compendium; 2004. URL: http://emc.medicines.org.uk/emc/industry/ default.asp?page=displaydoc.asp&documentid=1511. Accessed 24 August 2005.
23. Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews [CRD Report 4]. 2nd ed. York: Centre for Reviews and Dissemination; 2001.
24. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications; 1997.
25. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
27. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [TAX 327]. N Engl J Med 2004;351:1502-12.
28. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23:3343-51.
29. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustme compared with mitoxantrone and prednisone for advanced refractory prostate cancer [SWOG 9916]. N Engl J Med 2004;351:1513-20.
30. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168:2439-43.
31. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
32. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506-13.
33. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-42.
34. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004;10:8147-51.
35. Eisenberger MA, de Wit R, Berry W, Bodrogi I, Pluzanska A, Chi K, et al. A multicenter phase III comparison of docetaxel (D) plus prednisone (P) and mitoxantrone (MTZ) plus P in patients with hormone-refractory prostate cancer (HRPC) [abstract]. J Clin Oncol 2004;22(14S):4.
36. Eisenberger MA, de Wit R, Berry W, Bodrogi I, Pluzanska A, Chi K, et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC) [conference abstract]. Proc Am Soc Clin Oncol 2004;22(14S):4. URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fc310ee37a0ld/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=26&abstractID=2330. Accessed 4 May 2005.
37. Center for Drug Evaluation and Research. Approval package for: application number: 20-449/S-028 [Taxotere in combination with prednisone]: medical review(s) [Pdf on the Internet]. Center for Drug Evaluation and Research; 2004. URL: http://www.fda.gov/cder/foi/nda/2004/ 20-449s028_Taxotere_Medr.PDF. Accessed 26 May 2005.
38. Oudard S, Banu E, Vannetzel JM, Beuzeboc P, Dourthe LM, Voog E, et al. Results of a phase II randomized trial of docetaxel (D), estramustine (E) and prednisone (P) - two schedules - versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC) [abstract]. Ann Oncol 2002;13 Suppi 5:90.
39. Oudard S, Beuzeboc P, Dourthe LM, Voog E, Hardy Besard AC, Coscas I, et al. Preliminary results of a phase II randomized trial of docetaxel (D), estramustine (E) and prednisone (P) - two schedules - versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC) [conference abstract: no. 706]. In 2002 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. Available from: URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a0ld/ ?vgiiextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=16&abstractID=706. Accessed 4 May 2005.
40. Oudard S, Banu EB, Voog E, Hardy-Bessard H, Linassier C, Beuzeuboc P, et al. Phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) - two schedules - versus mitoxantrone (M) and prednisone in patients (PTS) with hormone refractory prostate cancer (HRPC) [conference abstract]. Eur Urol Suppl 2003;2:189.
41. Petrylak DP, Tangen C, Hussain M, Lara PN, Jones J, Talpin ME, et al. SWOG 99-16: randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA). J Clin Oncol 2004;22:3.
42. Southwest Oncology Group, National Cancer Institute, Cancer and Leukemia Group B, North Central Cancer Treatment Group. Combination therapy in treating Patients with advanced prostate cancer that have not responded to hormone therapy [web page on the Internet]. Bethesda, MD: National Institutes of Health. URL: http://www.clinicaltrials.gov/ct/show/ NCT00004001. Accessed 22 December 2004.
43. Berry DL, Moinpour CM, Jiang C, Vinson LV, Lara PN, Lanier S, et al. Quality of life (QOL) and pain in advanced stage prostate cancer: impact of missing data on evaluating palliation in SWOG 9916. J Clin Oncol 2004;22 (14 Suppl):401s.
44. Gregurich M, Gregurich M, Asmar L. Phase III study of mitoxantrone/ low-dose prednisone versus low-dose prednisone alone in patients with asymptomatic hormone-refractory carcinoma of tire prostate [conference abstract: no. 1321]. In 2000 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/ site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a0ld/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=2&abstractID=200942. Accessed 11 May 2005.
45. Dowling AJ, Panzarella T, Ernst DS, Neville AJ, Moore MJ, Tannock IF. A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. Ann Oncol 2001;12:773-8.
46. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654-63.
47. Tannock I, Osoba D, Ernst S, Neville A, Moore M, Armitage G, et al. Chemotherapy with mitoxantrone (M) and prednisone (P) palliates patients with hormone-resistant prostate cancer (HRPC): results of a randomized Canadian trial [conference abstract: no. 653]. Proceedings of ASCO 1995;14:245.
48. Stockler MR, Osoba D, Goodwin P, Corey P, Tannock IF. Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the prostate cancer specific quality of life instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. J Clin Epidemiol 1998;51:137-45.
49. Moore MJ, Tannock I, Osoba D, Stockler M, Ernst DS, Neville A, et al. Chemotherapy with mitoxantrone and low dose prechrisone provides useffil palliation for some patients with hormonally resistant prostate cancer (HRPC) [conference abstract]. Proc Am Urol Assoc 1996; 155 Suppl:610A.
50. Dowling AJ, Parizarella T, Tannock IF. Relationship between changes in serum prostatic specific antigen (PSA) and palliative response following treatment of symptomatic hormone-refractory prostate cancer (HRPC) [conference abstract: no. 1248]. In 1998 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a0ld/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=31&abstractID=13467. Accessed 7 February 2005.
51. Kantoff PW, Conaway M, Winer E, Picus J, Vogelzang NJ. Hydrocortisone (HC) with or without mitoxantrone (M) in patients (pts) with hormone refractory prostate cancer (HRPC): preliminary results from a prospective randomized Cancer and Leukemia Group B study (9182) comparing chemotherapy to best supportive care [abstract]. J Clin Oncol 1996;14:1748.
52. National Cancer Institute. Phase III randomized study of mitoxantrone and prednisone with or without clodronate in patients with hormone refractory metastatic prostate cancer and pain [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2001. [cited 2005 May 5]. URL: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=66102&version= HealthProfessional&protocolsearchid=1595737. Accessed 5 May 2005.
53. Ernst DS, Tannock IF, Venner PM, Winquist EW, Reyno L, Walker H, et al. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study [abstract]. In 2002 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/ac/1,1003,_12-002640-00_18-0016-00_19-00705,00.asp. Accessed 11 May 2005.
54. Eymard J-C, Joly F, Priou F, Zannetti A, Ravaud A, Kerbrat P, et al. Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): a final report [conference abstract: no. 4603]. Proc Am Soc Clin Oncol 2004;22(14S):4603. URL: http://www.asco.org/porta/site/ASCO/ menuitem.34d60f56 24ba07fd506fe310ee37a0ld/ ?vgnextoid=76f8201eb 61a7010VgnVCM1000 00ed730ad1RCRD&vmview= abst_detail_view&confID=26&abstractID=3219. Accessed 4 May 2005.
55. Salimichokami M. Combining angiogenesis inhibitors with cytotoxic chemotherapy enhances PSA response in hormone refractory prostate cancer (HRPC), a randomized study of weekly docetaxel alone or in combination with thalidomide [abstract]. Proc Am Soc Clin Oncol 2003:429.
56. Casciano R, Petrylak D, Neugut AI, Doyle J, Casciano J, Arikian S, et al. Systematic review of chemotherapy efficacy from controlled trials in hormone-refractory prostate cancer (HRPC) patients [conference abstract no. 2428]. In 2001 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmv iew=abst_detail_view&confID=10&index=y&abst ractID=2428. Accessed 19 July 2005.
57. National Cancer Institute. Phase III randomized study of docetaxel and prednisone with versus without bevacizumab in patients with hormone-refractory metastatic adenocarcinoma of the prostate [patient version] [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2005. URL: http://www.nci.nih.gov/search/ viewclinicaltrials.aspx?cdrid=427290&version= healthprofessional&protocolsearchid=1630976&print=1. Accessed 25 May 2005.
58. Cell Genesys. GVAX® prostate cancer vaccine vs docetaxel and prednisone in patients with metastatic honnone-reftactory prostate cancer [web page on the Internet]. Bethesda, MD; National Institutes of Health. URL: http://www.clinicaltrials.gov/ct/show/NCT00089856. Accessed 22 December 2004.
59. James N. A randomised phase II feasibility study of docetaxel (Taxotere) plus prednisolone vs docetaxel i(Taxotere) plus prednisolone plus zoledronic acid (Zometa) vs. docetaxel (Taxotere) plus prednisolone - + zoledronic acid (Zometa) plus strontium-89 in HRPC. [Ongoing trial - ISRCTN12808747]. URL: http://www.cotrolled-trials.com/isrctn/trial/ /0/ 12808747.html. Accessed 20 April 2005.
60. Cabrespine A, Guy L, Chollet P, Fleury J, Gachion F, Curé H, et al. Phase II study of paclitaxel carboplatin combination versus mitoxantrone in patients with hormone-refractory prostate cancer [conference abstract: no. 301]. In 2005 Prostate Cancer Symposium. Alexandria, VA: American Society of Clinical Oncology. URL: http:/ /www.asco.org/portal/ site/ASC0/menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=37&index=y&abstractID=20120. Accessed 11 May 2005.
61. Sanofi-Aventis. Sponsor submission to the National Institute fir Health and Clinical Excellence: Taxotere (docetaxel) in metastatic hormone refractory prostate cancer (mHRPC) [industry submission]. Sanofi-Aventis; 2005.
62. Song F, Altman DG, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472-5.
63. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91.
64. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol 1998;16:2272-9.
65. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098.
66. Santini D, Gentilucci UV, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14:1468-76.
67. Sarosdy MF, Lamm DL, Radwin HM, Von Hoff DD. Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies. Cancer 1982;50:1332-38.
68. Sartor O. Endpoints in prostate cancer clinical trials. Urology 2002;60 (3 Suppl 1):101-7.
69. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-34.
70. Briggs AH, Goeree R, Blackhouse G, O'Biren BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesphageal reflux disease. Med Decis Making 2002;22:290-308.
71. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397-409.
72. Gill PE, Murray W, Wright MH. Numerical linear algebra and optimization. Redwood City, CA: Addison-Wesley; 1991.
73. Bennet CL, Chapman G, Elstein AS, Knight SJ, Nadler RB, Sharifi R, et al. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol 1997;32 Suppl 3:86-8.
74. Chapman GB, Elstein AS, Kuzel TM, Sharifi R, Nadler RB, Andrews A, et al. Prostate cancer patients' utilities for health states: how it looks depends on where you stand. Med Decis Making 1998; 18:278-86.
75. Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Sharifi R, Bennett CL. A multi-attribute model of prostate cancer patients' preferences for health states. Qual Life Res 1999;8:171-80.
76. Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003;41:153-64.
77. Sandblom G, Carlsson P, Sennfalt K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer 2004;90:1163-8.
78. Volk RJ, Cantor SB, Cass AR, Spann SJ, Weller SC, Krahn MD. Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. J Gen Intern Med 2004;19:339-48.
79. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care 2005;43:347-55.
80. Joint Formulary Committee. British National Formulary. 49th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2005.
81. Chartered Institute of Public Finance and Accountancy. Health service financial database [CD-ROM]. London: Chartered Institute of Public Finance and Accountancy; 2004.
82. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993;12:459-67.
83. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87.
84. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy - prostate instrument. Urology 1997;50:920-8.
85. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
86. Spiegelhalter DAT, Best N, Lunn D. WinBUGS user manual: version 1.4. Cambridge: Medical Research Council Biostatistics Unit; 2001.
87. Claxton K, Sculpher M, Drumond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE) [discussion]. Lancet 2002;360:711-15.
88. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64.
89. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996;5:513-24.
90. Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development [CHE research paper no. 5]. York: University of York, Centre for Health Economics; 2005.
91. Ahmad K. New progress in treatment of hormone-refractory prostate cancer. Lancet Oncol 2004;5:706.
92. Anonymous. Systemic therapy in advanced or metastatic Prostate cancer: evaluation of drug efficacy. [STAMPEDE] [Ongoing trial - ISRCTN78818544]. 2002. URL: http://www.controlled-trials.com/isrctn/ trial/ /0/78818544.html. Accessed 16 May 2005.
93. Phase III studies with docetaxel: significant advantage for survival in androgen-independent prostate cancer. Dtsch Apoth Ztg 2004; 144:38-40 (in German).
94. Anonymous. Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer. Prescrire Int 2001;10:110-12.
95. Anonymous. Health-related QOL measurements: key to optimal management of prostate cancer. Drugs Ther Perspect 2000;16:13-16.
96. Arcenas AG, Karkera D, Anderson A, Krasnow SH. Preliminary results of a phase II trial of docetaxel (D) and mitoxantrone (M)/prednisone (P) in patients (pts) with hormone-refractory prostate cancer (HRPC) [conference abstract]. Plroc Am Soc Clin Oncol 2003;22:427 (abstract 1714). URL: http://www.asco.org/portal/site/ASCO/ meniuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=23&index=y&abstractID=101545. Accessed 4 April 2005.
97. Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W. National Cancer Institute intramural approach to advanced prostate cancer. Clin Prostate Cancer 2002;1:153-62.
98. Autorino R, di Lorenzo G, Damiano R, de Placido S, d'Armiento M. Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives. Urol Int 2003;70:1-14.
99. Aventis Pharma. Taxotere [web page on the Internet]. Bridgewater, NJ: Aventis Pharma; 2004. URL: http://www.taxotere.com/professional/home.do. Accessed 6 January 2005.
100. Aventis Pharma. Taxotere 80 mg [patient information leaflet]. Electronic Medicines Compendium; 2004. URL: http://emc.medicines.org.uk/emc/assets/ c/html/displaydoc.asp?documentid=3901. Accessed 6 January 2005.
101. Aventis Pharma. Taxotere 20 mg [patient information leaflet]. Electronic Medicines Compendium; 2004. URL: http://emc.medicines.org.uk/emc/assets/ c/html/displaydoc.asp?documentid=3900. Accessed 6 January 2005.
102. Beedassy A, Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol 1999;26:428-38.
103. Beer T, Pierce W, Lowe B, Henner W. Phase II study of weekly docetaxel (TAXOTERE) in hormone refractory metastatic prostate cancer (HRPC) [conference abstract: no. 1368]. In 2000 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7011VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=2&index=y&abstractID=201056. Accessed 4 May 2005.
104. Beer TM, Berry W, Wersinger EM, Bland LB. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2003;2:167-72.
105. Beer TM, Bubalo JS. Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. Curr Urol Rep 2002;3:232-8.
106. Beer TM, Bubalo JS. Prevention and management of prostate cancer chemotherapy complications. Urol Clin North Am 2004;31:367-78.
107. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12:1273-9.
108. Beitz J. Quality-of-life end points in oncology drug trials. Oncology 1999;13:1439-42.
109. Bernardi D, Talamini R, Zanetti M, Simonelli C, Vaccher E, Spina M, et al. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer - a phase II trial. Prostate Cancer Prostatic Dis 2004;7:45-9.
110. Berry WR, Beer TM. Weekly docetaxel in the elderly, outcomes in men with androgen independent prostate cancer (AIPC) [the same as or greater than] 70 vs < 70 years of age [conference abstract]. Proc Am Soc Clin Oncol 2003;22:745 (abstract 2996). URL: http://www.asco.org/portal/site/ ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD &vmview=abst_det ail_view&confID=23&abstractID=100775. Accessed 4 May 2005.
111. Bloomfield DJ, Krahn MD, Tannock IF. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone resistant prostate cancer (HRPC) based on a Canadian randomized trial (RCT) with palliative endpoints [conference abstract: no. 1130]. Proceedings of ASCO 1997;16:317a.
112. Bloomfield DJ, Kralin MD, Willan AR, Tannock IF. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone resistant prostate cancer based on a Canadian randomised trial with palliative endpoints. Eur J Cancer 1997;33:OP5.
113. Bosnjak S, Jelic S. Supportive care in patients with metastatic prostate cancer. Journal of BUON 2003;8:111-20.
114. Bracarda S, Lippe P, Contu A, DeAngelis V, Remondini S, Marrocolo F, et al. Docetaxel (D), estramustine (E), dexamethasone (DEX) and prednisone (P) in chemo (CT) and/or radiotherapy (RT) pretreated hormone refractory prostate cancer patients (HRPC): results of a preliminary study. Ann Oncol 2002;13 Suppl 3:E6.
115. Brandes L, Raghavan D, Klapp K, Snyder T, Ramsey E, Lieskovsky G. Apparently increased anticancer effect in phase II trial of mitoxantrone-DPPE for symptomatic hormone-refractory prostate cancer (CAP) [conference abstract: no. 1496A]. In 2000 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http:// www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba071d506fe31 0ee37a01d/?vgnextoid=76f8201eb6la7010VgnVCM100000ed730ad1RCRD& vmview=abst_detail_view&confID=2&index=y&abstractID=100303. Accessed 11 May 2005.
116. Cancer Research UK. CancerStats survival - UK [web page on the Internet]. London: Cancer Research UK; 2004. Available from: http:// info.cancerresearchuk.org/cancerstats/survival/. Accessed July 2005.
117. Canil CM, Tannock IF. Is there a role for chemotherapy in prostate cancer? Br J Cancer 2004;91:1005-11.
118. Carducci MA, DeWeese TL, Nelson JB. Prostate-specific antigen and other inarkers of therapeutic response. Urol Clin North Am 1999;26:291-302.
119. Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, et al. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer 2005;103:11-21.
120. Chatta G. [Commentary on] randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer [by] Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parries H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD. Urol Oncol 2004;22:502-3.
121. Clarke NW, Wylie JP. Chemotherapy in hormone refractory prostate cancer: where do we stand? Eur Urol 2004;46:709-11.
122. Collette L, van Andel G, Bottomley A, Oosterhof GON, Albrecht W, de Reijke TM, et al. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 2004;22:3877-85.
123. Copur MS, Ledakis P, Lynch J, Hauke R, Tarantolo S, Bolton M, et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Sentin Oncol 2001;28 (4 Suppl 15):16-21.
124. Crawford ED. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice [editorial comment]. J Urol 2000;163:1485.
125. Crawford ED. Patient selection for therapy in prostate cancer. Eur Urol Suppl 2002;1:2-6.
126. Culine S. News on the medical treatment of urological tumors. Bull Cancer 2000;87:71-5 (in French).
127. Culine S, Droz JP. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Ann Oncol 2000;1:1523-30.
128. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9.
129. D'Amico AV, Halabi S, Volgelzang NJ. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: results of a pooled analysis of CALGB HRPC trials [abstract]. J Clin Oncol 2004;22 Suppl 14:4506.
130. de Mulder PHM, Schalken JA, Sternberg CN. Treatment options in hormone resistant prostate cancer. Ann Oncol 2002; 13 Suppl 4:95-102.
131. de Wit R. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy. Eur J Cancer 2005;41:502-7.
132. DeGrendele H. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002. Clin Prostate Cancer 2003;1:212-14.
133. Denes AE. Chemotherapy with mitoxantrone in hormone-refractory prostate cancer. J Clin Oncol 1997;15:410.
134. Diaz M, Patterson SG. Management of androgen-independent prostate cancer. Cancer Control 2004;11:364-73.
135. Dogliotti L, Mosca A. Management of hormone-refractory prostate cancer. Tumori 2003;2 (4 Suppl): S147-9.
136. Dowling AJ, Czaykowski PM, Krahn MD, Moore MJ, Tannock IF. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 2000; 163:1481-5.
137. Efficace F, Bottomley A, van Andel G. Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer 2003;97:377-88.
138. Eymard JC, Joly F, Priou F, Zannetti A, Ravaud A, Kerbrat P, et al. Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): a final report. J Clin Oncol 2004;22 Suppl 14:4603.
139. Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 2002;60:553-61.
140. Ferrero JM, Foa C, Thezenas S, Ronchin P, Peyrade F, Valenza B, et al. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology 2004;66:281-7.
141. Ferrero JM, Foa C, Thezenas S, Ronchin P, Peyrade F, Valenza B, et al. A phase II of weekly docetaxel for hormone refractory metastatic prostate cancer (HRMPC). Eur Urol Suppl 2003;2:24.
142. Fichtner J. The management of prostate cancer in patients with a rising prostate-specific antigen level. BJU Int 2000;86:181-90.
143. Font A, Murias A, Arroyo FRG, Martin C, Areal J, Sanchez JJ, et al. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Ann Oncol 2005;16:419-24.
144. Fossa SD, Slee PHT, Brausi M, Horenblas S, Hall RR, Hetherington JW, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 2001;19:62-71.
145. Freeman SL, Wesner J, Polikoff JA. A phase II study of the combination of docetaxel/mitoxantrone/low-dose prednisone in men with hormone-refractory prostate cancer (HRPC) [conference abstract]. Proc Am Soc Clin Oncol 2003;22:432 (abstract 1735). URL: http://www.asco.org/ portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=23&index=y&abstractID=102202. Accessed 4 May 2005.
146. Friedland D, Cohen J, Miller R, Gluckman R, Zidar B, Lembersky B, et al. A phase II trial of taxotere in hormone refractory prostate cancer: correlation of antitumor activity to phosphorylation of bcl2 [conference abstract: no. 1237]. Proceedings of ASCO 1999;18:1237.
147. Gaffar YA, Fishman M, Kish JA, Patterson S, Balducci L, Extermann M, et al. Toxicity and preliminary data for a phase II trial of weekly docetaxel and dexamethasone for hormone-insensitive metastatic prostate cancer [conference abstract]. Proc Am Soc Clin Oncol 2003;22:426 (abstract 1711). URL: http://www.asco.org/portal/site/ASCO/ menuitem.34 d60f5624ba07fd 506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vm view=abst_detail_view&confID=23&index=y&a bstractID=101374. Accessed 26 May 2005.
148. Garcia-Altes A, Jovell AJ. Could we measure the efficiency of prostate cancer treatment? A critical appraisal of economic evaluation studies. Prostate Cancer Prostatic Dis 2001;4:217-20.
149. Gilligan TD, Halabi S, Kantoff PW, Dawson NA, Kaplan EB, Small EJ, et al. African-American race is associated with longer survival in patients with metastatic hormone-refractory prostate cancer (HRCaP) in four randomized phase III Cancer and Leukemia Group B (CALGB) trials [abstract]. Proc Am Soc Clin Oncol 2002;21:A-725.
150. Goodin S, Medina P, Shih WJ, Capanna T, Abraham S, Rao KV, et al. Docetaxel in patients with PSA progression after local therapy for prostate cancer: a completed phase II study [conference abstract]. Proc Am Soc Clin Oncol 2003;22:411 (abstract 1651). URL: http://www.asco.org/ portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD &vmview=abst_detail_view&confID=23&index=y&abstr actID=103026. Accessed 4 May 2005.
151. Gravis G, Bladou F, Salem N, Macquart-Moulin G, Genre D, Camerlo J, et al. Efficacy, quality of life (QOL) and tolerance with weekly docetaxel (D) in metastatic hormone refractory prostate cancer (HRPC) patients [conference abstract: no. 2433]. In 2001 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http:// www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310e037 a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview =abst_detail_view&confID=10&index=y&abstractID=2433. Accessed 23 December 2004.
152. Gravis G, Bladou F, Salem N, Macquart-Moulin G, Serment G, Camerlo J, et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Evaluation of clinical benefit, quality of life, and tolerance. Cancer 2003;98:1627-34.
153. Gravis G, Bladou F, Salem N, Macquar G, Serment G, Camerio J, et al. Chemotherapy with a weekly administration of docetaxel for metastatic hormone refractory prostate cancer (HRPC). Evaluation of tolerance, quality of life (QoL), and clinical benefit. In XVIIth Congress of the European Association of Urology, 23-26 February 2002, Birmingham, UK. p. 158.
154. Guimaraes T, Bento MJ, Pinho T, Guedes de Carvalho R, Pinto E Phase II study of docetaxel and estramustine in metastatic androgen-independent prostate cancer. In XVlIth Congress of the European Association of Urology, 23-26 February 2002. Birmingham, UK. 2002. p. 159.
155. Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS, et al. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol 2003;52:159-66.
156. Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004;9:538-45.
157. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7.
158. Heidenreich A. Multimodality treatment in advanced prostate cancer. Eur Urol Suppl 2004;3:51-7.
159. Heidenreich A, Carl S, Gleissner S, Moormann O. Docetaxel (DOC) and mitoxantrone (MIT) in the management of hormone-refractory prostate cancer (HRPC) [conference abstract]. Proc Am Soc Clin Oncol 2003;22:412 (abstract 1655). URL: http://www.asco.org/portal/site/ASCO/ menuitem.34 d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76ff8201cb61a7010VgnVCM100000ed730ad1RCRD&vmview =abst_detail_view&confID=23&index=y&abstractID=101719. Accessed 4 May 2005.
160. Heidenreich A, Ohlmann C, Olbert P, Hegele A. Docetaxel (DOC) and mitoxantrone (MIT) in the management of hormone-refractory prostate cancer [poster abstract]. In l2th European Cancer Conference (ECCO), 21-25 September 2003, Copenhagen, Denmark. p. S264.
161. Heidenreich A, Schrader A, Olbert P Ohlmann C, Hegel A, Hofmann R. Docetaxel (DOC) and mitoxantrone (MIT) in the management of hormone refractory prostate cancer (HRPCA). In 19th Congress of the European Association of Urology, 24-27 March 2004, Vienna, Austria. p. 156.
162. Heidenreich A, Wille S, Ohlmann C, Hert A, Hofmann R. Docetaxel and mitoxantrone in the management of hormone refractory prostate cancer: results of a prospective phase-II trial [abstract]. J Urol 2003;169 (4 Suppl):1491.
163. Heidenreich A, Wille S, Ohlmann C, Elert A, Hofmann R. Docetaxel and mitoxantrone in the management of hormone refractory prostate cancer: results of a prospective phase-II trial [conference abstract]. J Urol 2003;169 (4 suppl):399.
164. Hennequin C. Management of hormone-refractory disease. BJU Int 2004;94 Suppl 3:16-17.
165. Higano CS, Beer TM, Garzotto M, Ryan CW, Pitzel M, Works CR, et al. Need for awareness and monitoring of ocular toxicities (OT) due to weekly docetaxel administration: experience during a trial of neoadjuvant docetaxel (D) and mitoxantrone (M) for patients with high-risk prostate cancer (PC) [poster discussion]. J Clin Oncol 2004;22 (14 Suppl):401s.
166. Higano CS, Beer TM, Garzotto M, Ryan CW, Pitzel M, Works CR, et al. Need for awareness and monitoring of ocular toxicities (OT) due to weekly docetaxel administration: experience during a trial of neoadjuvant docetaxel (D) and mitoxantrone (M) for patients with high-risk prostate cancer (PC) [conference abstract]. J Clin Oncol 2004;22 (14 Suppl): abstr 4577. URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCR D&vmview=abst_detail_view&confID=26&index=y&abstract ID=4040. Accessed 11 May 2005.
167. Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol 1999;26 (5 Suppl 17):55-60.
168. Joly F, Tannock IF. Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol 2004;15:1582-4.
169. Karavasilis V, Briasouhs E, Siarabi O, Pavlidis N. Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy. Clin Prostate Cancer 2003;2:46-9.
170. Kasamon KM, Dawson NA. Update on hormone-refractory prostate cancer. Curr Opin Urol 2004;14:185-93.
171. Khalaf A, Pfister C, Hellot MF, Dunet F, Moussu J, Grise P. Value of mitoxantrone in metastatic hormone-resistant prostate cancer. Prog Urol 2002;12:37-42.
172. Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003;170:1709-16.
173. Kish JA, Bukkapatnam R, Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control 2001;8:487-95.
174. Knox JJ, Moore MJ. Treatment of hormone refractory prostate cancer. Semin Urol Oncol 2001;19:202-11.
175. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, et al. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001;7:800-5.
176. Kolodziej MA, Berry WR, Cunningham T, Mirabel M, Asmar L. A phase I trial of weekly mitoxantrone (M) and docetaxel (D) in patients (pts) with hormone refractory carcinoma of the prostate (HRPC) [conference abstract: no. 2482]. In 2002 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/ site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=16&index=y&abstractID=2482. Accessed 4 May 2005.
177. Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 2001;12:633-41.
178. Kosty MP, Ferreira A, Bryntesen T. Weekly docetaxel and low-dose estramustine phosphate in hormone refractory prostate cancer: a phase II study [conference abstract: no. 2360]. In 2001 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http:// www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310e e37a01d?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCR D&vmview=abst_detail_view&confID=10&in dex=y&abstractID=2360. Accessed 4 May 2005.
179. Kozloff M, Robin EL, Raminski D, Rao Uppuluri VS, Sylora J, Kozloff M. A phase II study using mitoxantrone and ketoconazole in hormone resistant metastatic adenocarcinoma of the prostate [conference abstract: no. 2521]. In 2000 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmnview= abst_detail_view&confID=2&abstractID=201820. Accessed 11 May 2005.
180. Kozloff M, Robin EL, Raminski D, Rao Uppuluri VS, Sylora J, Starr A, et al. A phase II study using mitoxantrone and ketoconazole in hormone resistant metastatic adenocarcinoma of the prostate [conference abstract: no. 2364]. In 2001 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/ site/ASCO/menuitem.34d60f5624baO7fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM10 0000ed730ad1RC RD&vmview=abst_detail_view&confID=10&index=y&ab stractID=2364. Accessed 11 May 2005.
181. Kuebler H, van Randenborgh H, Paul R, Breul J, Hartung R. Docetaxel-monotherapy given every 21 days in patients with metastatic hormone refractory prostate cancer (m-HRPC) - response and toxicity. Eur Urol Suppl 2003;2:25.
182. Laber DA, la Rocca RV, Glisson S, Hargis J, Schonard C. Phase II study of higher dose docetaxel in clinically deteriorating patients with hormone refractory prostate cancer (HRPC) [conference abstract: no. 2449]. In 2002 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a710VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=16&index=y&abstractlD=2449. Accessed 4 May 2005.
183. Laber DA, La Rocca RV, Glisson SD, Hargis J, Schonard C. Higher dose docetaxel. in patients with hormone refractory prostate cancer (HRPC). Long-term results of a phase II study [conference abstract], Proc Am Soc Clin Oncol 2003;22:413 (abstract 1661). URL: http://www.asco.org/portal/ site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=23&index=y&abstractID=100154
184. Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium screening and phase II trial. Cancer 2004;100:2125-31.
185. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer [pdf on the Internet]. Alexandria, VA: American Society of Clinical Oncology; 2004. URL: http://www.asco.org/ asco/downloads/JCO.2004.04.579v1.pdf. Accessed 11 May 2005.
186. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology 9002;16 (6 Suppl):63-72.
187. Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn QJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma - results of a meta-analysis. Cancer 2004;101:2755-59.
188. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003;29:171-87.
189. Mattioli R, Imperatori L, Casadei V. Preliminary experience: chemotherapy with mitoxantrone and vinblastina in elderly with advanced hormonally resistant prostate cancer. Ann Oncol 1998;9:77.
190. MedlinePlus. Corticosteroids: glucocorticoid effects (systemic) [web page on the Internet]. Bethesda, MD: US National Library of Medicine; 2005. URL: http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/ 202018.html. Accessed 17 June 2005.
191. Miller K, Raabe N, Trachtenberg J, Trump D, Wilding G, Das-Gupta A. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with mitoxantrone and prednisone in patients with hormone refractory prostate cancer (HRPC). Ann Oncol 2002;13 Suppl 5:91.
192. Miller K, Steiner U, Machtens S, Backhaus B, Siegsmund M, Johannsen M, et al. Combination chemotherapy with weekly docetaxel and intermittent estramustine in patients with hormone-refractory prostate cancer (HRPC): a multicenter phase II study [conference abstract]. Proc Am Soc Clin Oncol 2003;22:413 (abstr 1660). URL: http://www.asco.org/portal/site/ ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&v mview=abst_detail_view&confID=23&in dex=y&abstractID=103648. Accessed 4 May 2005.
193. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229-39.
194. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689-94.
195. Nabhan C, Petrylak DP, Hussain M, Crawford ED. Chemotherapy for advanced prostate cancer [letter and reply]. N Engl J Med 2005;352:200-1.
196. National Cancer Institute. Phase II study of docetaxel in patients with hormone reftactory metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 1999. URL: http:// www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 66913&version=HealthProfessional&protocolsearchid=1609754. Accessed 13 May 2005.
197. National Cancer Institute. Phase II randomized study of docetaxel with or without thalidomide in patients with androgen-independent metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2000. URL: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=67602&version=HealthProfessi onal&protocolsearchid=1609754. Accessed 13 May 2005.
198. National Cancer Institute. Phase II randomized study of SGN-15 (cBr96-doxorubicin immunoconjugate) combined with docetaxel vs docetaxel alone in patients with hormone-reftactory prostate carcinoma [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2002. URL: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=69077&version=HealthProfes sional&protocolsearchid=1609754. Accessed 13 May 2005.
199. National Cancer Institute. Phase II study of docetaxel (Taxotere) in patients with hormone-reftactory prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2002. URL: http:// www.cancer.gov/searchViewClinicalTrials.aspx?cdrid=63293&version= HealthProfessional&protocolsearchid=1609754. Accessed 13 May 2005.
200. National Cancer Institute. Phase II study of docetaxel (Taxotere) in patients with hormone-refractory metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2002. URL: http://www.cancer.gov/searchViewClinicalTrials.aspx?cdrid= 64445&version=HealthProfessional&protocolsearchid=1609754. Accessed 13 May 2005.
201. National Cancer Institute. Phase II crossover extension study of docetaxel and imatinib mesylate in patients with androgen-independent prostate cancer and bone metastases that progressed on the docetaxel and placebo arm of MDA-ID-030008 [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.nci.nih.gov/ clinical_trials/view_clinicaltrials.aspx?cdrid=365625&version= heal thprofessional. Accessed 12 May 2005.
202. National Cancer Institute. Phase II randomized study of docetaxel with versus without imatinib mesylate in patients with androgen-independent prostate cancer and bone metastases [web page on the Inernet]. Bethesda, Maryland: National Cancer Institute; 2004. [cited 2005 12 May]. URL: http://www.nci.nih.gov/clinical_triais/view_clinicaltrials.aspx?cdrid= 354505&version=healthprofessional. Accessed 12 May 2005.
203. National Cancer Institute. Phase II study of GTI-2040, docetaxel, and prednisone in patients with hormone-reftactory prostate cancer [web page on the Inernet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.nci.nih.gov/clinical_trials/view_clinicaltrials.aspx?cdrid= 372951&version=healthprofessional. Accessed 12 May 2005.
204. National Cancer Institute. Phase II randomized study of docetaxel with or without oblimersen in patients with hormone-reftactory adenocarcinoma of the prostate [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=367489&version =HealthProfessional&protocolsearchid=1608204. Accessed 13 May 2005.
205. National Cancer Institute. Docetaxel in treating patients with stage IV prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.clinicaltrials.gov/ct/show/ NCT00003781. Accessed 16 May 2005.
206. National Cancer Institute. Docetaxel in treating patients with stage II or stage III Prostate cancer [web page on the Internet]. Bethesda, Maryland: National Cancer Institute; 2004. URL: http:// www.clinicaltrials.gov/ct/show/NCT00005096. Accessed 16 May 2005.
207. National Cancer Institute. Combination chemotherapy in treating patients with prostate cancer that has not responded to hormone therapy [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.clinicaltrials.gov/ct/show/NCT00005960. Accessed 16 May 2005.
208. National Cancer Institute. Combination chemotherapy plus bevacizumab in treating patients with metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http:// www.clinicaltrials.gov/ct/show/NCT00016107. Accessed 16 May 2005.
209. National Cancer Institute. Combination chemotherapy plus warfarin in treating patients with prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http:// www.clinicaltrials.gov/ct/show/NCT00014352. Accessed 16 May 2005.
210. National Cancer Institute. Chemotherapy with or without biological therapy in treating patients with metastatic prostate cancer that has not responded to hormone therapy [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.clinicaltrials.gov/ ct/show/NCT00005847. Accessed 16 May 2005.
211. National Cancer Institute. Phase III randomized study of hormonal therapy and docetaxel versus hormonal therapy alone in patients with metastatic prostate adenocarcinoma [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2005. URL: http://www.nci.nih.gov/search/ ViewClinicalTrials.aspx?cdrid=416096&version=HealthPro fessional&protocolsearchid=2124369. Accessed 12 May 2005.
212. National Cancer Institute. Docetaxel, radiation therapy, and hormone therapy in treating patients with locally advanced prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2005. URL: http://www.clinicaltrials.gov/ct/show/NCT00099086. Accessed 16 May 2005.
213. National Cancer Institute. Hormone therapy plus chemotherapy in treating patients with prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2005.URL: http://www.clinicaltrials.gov/ct/ show/NCT00030654. Accessed 16 May 2005.
214. National Cancer Institute. Hormone therapy with or without mitoxantrone and prednisone in treating patients who have undergone radical prostatectomy for prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2005. URL: http://www.clinicaltrials.gov/ ct/show/NCT00004124. Accessed 16 May 2005.
215. National Cancer Institute. Phase III randomized study of matrix metalloprotease inhibitor AG3340 in combination with mitaxantrone and prednisone in patients with hormone reftactory prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2000. URL: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 66320&version=HealthProfessional&protocolsearchid=1595737. Accessed 5 May 2005.
216. National Cancer Institute. Phase II chemotherapy with mitaxantrone in metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2002. URL: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=71604&version=Health Professional&protocolsearchid=1595737. Accessed 5 May 2005.
217. National Cancer Institute. Phase II chemotherapy with CACP/DHAD in patients with metastatic hormone-resistant carcinoma of the prostate [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2002. URL: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=73467&version=Health Professional&protocolsearchid=1595737. Accessed 6 May 2005.
218. National Cancer Institute. Phase II randomized study of ixabepilone (BMS-247550) versus mitaxantrone and prednisone in patients with taxane-resistant, hormone-refractory metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=285731&version=Heal thProfessional&protocolsearchid=1597413. Accessed 6 May 2005.
219. National Cancer Institute. Phase I study of docetaxel, estramustine, mitaxantrone, and prednisone in patients with advanced prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2005. URL: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=66717&version=HealthProfe ssional&protocolsearchid=1595737. Accessed 6 May 2005.
220. National Cancer Institute. Docetaxel and prednisone with or without bevacizumab in treating patients with prostate cancer that did not respond to hormone therapy [patient version] [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2005. URL: http://www.nci.nih.gov/search/viewclinicaltrials.aspx?cdrid= 427290&version=patient&protocolsearchid=1630985&print=1. Accessed 25 May 2005.
221. National Cancer Institute. Ixabepilone compared with mitoxantrone and prednisone in treating patients with refractory metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Institutes of Health. URL: http://www.clinicaltrials.gov/ct/show/NCT00058084. Accessed 22 December 2004.
222. National Cancer Institute. Docetaxel, bevacizumab, thalidomide, and prednisone in treating patients with metastatic androgen-independent prostate cancer [web page on the Internet]. Bethesda, MD; National Institutes of Health. URL: http://www.clinicaltrials.gov/ct/show/ NCT00091364. Accessed 14 January 2005.
223. National Cancer Institute (NCI). GTI-2040, docetaxel, and prednisone in treating patients with prostate cancer [web page on the Internet]. Bethesda, MD: National Institutes of Health; [cited 2005 Jan 14]. URL: http://www.clinicaltrials.gov/ct/show/NCT00087165. Accessed 14 January 2005.
224. National Cancer Institute (NCI), Herbert Irving Comprehensive Cancer Center. Combination chemotherapy in treating patients with advanced prostate cancer [web page on the Internet]. Bethesda, Maryland; National Institutes of Health; [cited 2004 Dec 22]. URL: http://www.clinicaltrials.gov/ct/show/NCT00003633. Accessed 22 December 2005.
225. Newling DWW. Clinical trials in prostatic cancer - interpretations and misinterpretations. Prostate Cancer Prostatic Dis 1999;2:120-25.
226. Oh WK. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000;88 (12 Suppl):3015-21.
227. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160:1220-9.
228. Olson KB, Pienta KJ. Recent advances in chemotherapy for advanced prostate cancer. Curr Urol Rep 2000;1:48-56.
229. Parvez T, Al-sisi H, Ibraheim I. What next after hormonotherapy in cancer prostate? J Coll Physicians Surg Pak 2003; 13:606-10.
230. Petrioli R, Pozzessere D, Messinese S, Sabatino M, di Palma T, Marsili S, et al. Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy. Oncology 2003;64:300-5.
231. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999;54(6A Suppl:30-5.
232. Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 2000;27 (2 Suppl 3):24-9.
233. Petrylak DP. Taxane-based combination therapy for hormone-refractory prostate cancer. In XVII Symposium of the Chemotherapy Foundation: Innovative Cancer Therapy for Tomorrow, 3-6 November 1999, New York, NY, USA. 2000. p. 79-80.
234. Petrylak DP. Chemotherapy for the treatment of hormone-refractory prostate cancer. Eur Urol Suppl 2002;1:15-23.
235. Picus J, Schultz M. Docetaxel (Taxotere) as nionotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26(5 Suppl 17):14-18.
236. Picus J, Schultz M. A phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC): long term results [conference abstract: no. 1206]. Proceedings of ASCO 1999;18:1206.
237. Pozzessere D, Petrioli R, Messinese S, Sabatino M, Ceciarini F, Marsili S, et al. Weekly docetaxel in patients with hormone-resistant prostate cancer who had exposed to prior chemotherapy. Ann Oncol 2002;13 Suppl 3:E22.
238. Price N. Docetaxel improves survival in metastatic androgen-independent prostate cancer. Clin Prostate Cancer 2004;3:18-20.
239. Raghavan D, Brandes L, Klapp K, Snyder T, Styles E, Lieskovsky G, et al. Mitoxantrone plus DPPE in hormone-refractory prostate cancer (HR-CAP) with symptomatic metastases - response in 70% of cases [conference abstract: no. 786]. In 2002 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/ portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=16&index=y&abstractID=786. Accessed 11 May 2005.
240. Rago RP, Einstein A, Lush R, Beer TM, Ko YJ, Henner WD, et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2003;51:297-305.
241. Rajasenan KK, Friedland DM, Lembersky BC, Pinkerton RA, Voloshin MD, Freeman PF. Weekly docetaxel alone or with estramustine has significant activity in patients with hormone-refractory prostate cancer previously treated with conventionally dosed docetaxel [conference abstract: no. 2434]. In 2001 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.as co.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=10&index=y&abstractID=2434. Accessed 4 May 2005.
242. Rexer H. Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO. Urologe A 2004;43:1132-3 (in German).
243. Rosenberg JE, Kelly WK, Michaelson D, Wilding G, Hussain M, Gross M, et al. A randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane-refractory hormone refractory prostate cancer (HRPC) [conference abstract: no. 4566]. In 2005 Prostate Cancer Symposium. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=34&index=y&abstractID=31897. Accessed 11 May 2005.
244. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain M, Wilding G, et al. NCI 6046: multicenter randomized phase II study of ixabepilone (BMS-247550) or mitoxantrone and prednisone (MP) in patients with taxane-refractory hormone refractory prostate cancer. [Poster] 2005.
245. Rosenthal MA. Advances in the management of prostate cancer. Aust N Z J Med 2000;30:593-9.
246. Ruchlin HS, Pellissier JM. An economic overview of prostate carcinoma. Cancer 2001;92:2796-810.
247. Salimichokami M. Combining angiogenesis inhibitors with cytotoxic chemotherapy enhances PSA response in hormone refractory prostate cancer (HRPC), a randomized study of weekly docetaxel alone or in combination with thalidomide [conference abstract]. Proc Am Soc Clin Oncol 2003;22:429 (abstract 1725). URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb6ta7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=23&index=y&abstractID=101809. Accessed 4 May 2005.
248. Samelis G, Dimopoulos M, Skarios D, Bafaloukos D, Anagnostopoulos A, Aravantinos G, et al. Phase-II study with mitoxantrone and estramustine in hormonorefractory prostate cancer patients. Hellenic Cooperative Oncology Group (HEGOG). Ann Oncol 2000;11 Suppl 4:337P.
249. Sava T, Basso U, Porcaro A, Cetto GL. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Expert Rev Anticancer Ther 2005;5:53-62.
250. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995;46:142-8.
251. Scholz MC, Guess B, Barrios F, Strum S, Leibowitz R. Low-dose single-agent weekly docetaxel (Taxotere) is effective and well tolerated in elderly men with prostate cancer [conference abstract: no. 2441]. In 2001 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/p ortal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD &vmview=abst_detail_view&confID=10&index=y&a bstractID=2441. Accessed 4 May 2005.
252. Schwartz EL. Anti-angiogenic actions of Taxotere [web page on the Internet]. International Cancer Research Portfolio; [cited 2005 12 May].URL: http://www.cancerportfolio.org/ abstract.jsp?SID=74346&ProjectID=75542. Accessed 12 May 2005,
253. Sheen WC, Chen JS, Wmg HM, Yang TS, Liaw CC, Lin YC. A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer. Jpn J Clin Oncol 2004;34:337-41.
254. Sherman EJ, Pfister DG, Ruchlin HS, Rubin DM, Radzyner MH, Kelleher GH, et al. The collection of indirect and nonmedical direct costs (COIN) form. A new tool for collecting the invisible costs of androgen independent prostate carcinoma. Cancer 2001;91:841-53.
255. Small EJ, Reese DM, Vogelzang NJ. Hormone-refractory prostate cancer: an evolving standard of care. Semin Oncol 1999;26(5 Suppl 17):61-7.
256. Smith DC. Chemotherapy for hormone refractory prostate cancer. Urol Clin North Am 1999;26:323-31.
257. Stein C, Benson M, Katz A, Fine R, Olsson C. Phase I trial of docetaxel (D)/estramustine (E) + mitoxantrone (M)/prednisone (P) in hormone refractory prostate cancer (HRPC) [conference abstract: no. 483]. In 2000 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vniview= abst_detail_view&confID=2&index=y&abstractID=202825. Accessed 4 May 2005.
258. Syed S. Combination chemotherapy for hormone-refractory prostate carcinoma. Progress and pitfalls. Cancer 2003;98:2088-90.
259. Tannock IF. Management of metastatic prostate cancer. Journal of BUON 2001;6:227-30.
260. Tay MH, George DJ, Gilligan TD, Kelly SM, Appleby L, Taplin ME, et al. Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. J Clin Oncol 2004;22:4679.
261. Trump DL, Wilding G, Miller K, Small E, Soulie P, Trachtenberg J, et al. Pilot trials of ZD1839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisone or docetaxel/estramustine in patients with hormone-refractory prostate cancer. J Urol 2003;169 (4 Suppl):244.
262. Tyagi P, Price N, Reddy K, Klein J. Highlights from the XII European Cancer Conference Copenhagen, Denmark. Clin Prostate Cancer 2003;2:137-41.
263. US Food and Drug Administration. FDA public workshop on clinical trial endpoints in prostate cancer: June 21-22, 2004 - Bethesda, Maryland: summary [web page on the Internet]. Rockville, MD: US Food and Drug Administration; 2004. URL: http://www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4095B1_03_04-FDA-Tab4.htm. Accessed 26 May 2005.
264. Valerio MR, Cicero G, Armata MG, Fulfaro F, Bajardi E, Badalamenti G, et al. Weekly docetaxel in chemo-hormono-resistant prostate cancer [conference abstract]. Proc Am Soc Clin Oncol 2003;22:428 (abstract 1718). URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vm view=abst_detail_view&confID=23&index=y&abstr actID=101634. Accessed 4 May 2005.
265. van Poppel H. Recent docetaxel studies establish a new standard ofcare in hormone refractory prostate cancer. Can J Urol 2005;12 Suppl 1:81-5.
266. Vogelzang NJ. One hundred thirteen men with hormone-refractory prostate cancer died today. J Clin Oncol 1996;14:1753-5.
267. Vogelzang NJ. Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag. Semin Oncol 1999;26 (5 Suppl 17):1-2.
268. Vogelzang NJ. Corticosteroids in advanced cancer. The Wooldridge/ Anderson/Perry article reviewed. Oncology 2001;15:235-6.
269. Vogelzang NJ, Crawford ED, Zietman A. Current clinical trial design issues in hormone-refractory prostate carcinoma. Cancer 1998;82:2093-101.
270. Vollmer RT, Kantoff PW, Dawson NA, Vogelzang NJ. Importance of serum hemoglobin in hormone refractory prostate cancer. Clin Cancer Res 2002;8:1049-53.
271. Walczak JR, Carducci MA. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/ Clinical Trials Support Unit study. Urology 2003;62 Suppl 1:141-6.
272. Walsh PC. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. J Urol 2005;173:457.
273. Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J. Adjuvant mitozantrone chemotherapy in advanced prostate cancer [conference abstract: no. 1322]. In 2000 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/ site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=2&index=y&abstractID=200242. Accessed 11 May 2005.
274. Wang J, Waxman J. Chemotherapy for prostate cancer. Clin Oncol (R Coll Radial) 2001;13:453-4.
275. Warren G Magnuson Clinical Center. Docetaxel, thalidomide, prednisone, and bevacizumab to treat metastatic prostate cancer [web page on the Internet]. Bethesda, MD; National Institutes of Health. URL: http://www.clinicaltrials.gov/ct/show/NCT00089609. Accessed 14 January 2005.
276. Weitzman AL, Shelton G, Zuech N, Owen CE, Judge T, Benson M, et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 2000;163:834-7.
277. Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Stat Med 2001;20:1563-74.
278. Willan AR, O'Brien BJ, Leyva RA. Cost-effectiveness analysis when the WTA is greater than the WTP. Stat Med 2001;20:3251-9.
279. Willan AR. Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data. Control Clin Dials 2001;22:228-37.
280. Wiseman LR, Spencer CM. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997;10:473-85.
281. Wolf W, Presant CA, Victor W, le Berthon BJ. Response to anticancer treatment with docetaxel (DOC) administered every 3 weeks (Q3w) and weekly (Q1w) is associated with functional assessment of changes in tumoral blood flow/perfusion. In 94th Annual Meeting of the American Association for Cancer Research, 11-14 July 2003, Washington, DC: American Association for Cancer Research; 2003. p. 1061.
282. Wolff JM. Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer. Onkologie 2003;26 Suppl 7:37-40 (in German).
283. Zivin JG. Cost-effectiveness analysis with risk aversion. Health Econ 2001;10:499-508.